• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高危前列腺癌。最佳治疗方法。新证据。

High-risk prostate cancer. Optimal treatment. New evidences.

作者信息

Álvarez-Maestro Mario, Quesada Olarte Jose, Gómez Rivas Juan, Carrión Diego M, Juarez Soto Alvaro, Rios González Emilio, Aguilera Bazan Alfredo, Martínez-Piñeiro Luis

机构信息

Department of Urology. Hospital Universitario La Paz. Madrid. Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ). Madrid. Spain. Universidad Autónoma de Madrid. Madrid. Spain.

Department of Urology. Hospital Universitario La Paz. Madrid. Spain. Universidad Autónoma de Madrid. Madrid. Spain.

出版信息

Arch Esp Urol. 2019 Mar;72(2):203-210.

PMID:30855022
Abstract

There are multiple definitions of high risk prostate cancer and each definition is associated with a different prognosis. Men classified as having high-risk disease warrant treatment because durable outcomes can be achieved. Radical prostatectomy, radiation therapy and androgen deprivation therapy play pivotal roles in the management of men with high-risk disease, and potentially in men with metastatic disease.

摘要

高危前列腺癌有多种定义，且每种定义都与不同的预后相关。被归类为患有高危疾病的男性需要接受治疗，因为可以实现持久的治疗效果。根治性前列腺切除术、放射治疗和雄激素剥夺疗法在高危疾病男性的治疗中起着关键作用，对转移性疾病男性也可能如此。

相似文献

1
High-risk prostate cancer. Optimal treatment. New evidences.高危前列腺癌。最佳治疗方法。新证据。
Arch Esp Urol. 2019 Mar;72(2):203-210.
2
Approach to the Patient with High-Risk Prostate Cancer.高危前列腺癌患者的诊疗方法
Urol Clin North Am. 2017 Nov;44(4):635-645. doi: 10.1016/j.ucl.2017.07.009.
3
Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.根治性前列腺切除术后前列腺癌复发的男性接受雄激素剥夺治疗的结果和预后因素。
J Urol. 2018 Nov;200(5):1075-1081. doi: 10.1016/j.juro.2018.04.070. Epub 2018 Apr 27.
4
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.临床高危前列腺癌且 pT3 手术切缘阳性患者接受根治性前列腺切除术加辅助雄激素剥夺治疗的预后预测因素。
J Urol. 2012 Jul;188(1):84-90. doi: 10.1016/j.juro.2012.02.2572. Epub 2012 May 12.
5
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.死亡率与雄激素剥夺疗法作为临床局限性前列腺癌初始治疗后生化复发的挽救性治疗手段
J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.
6
Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?前列腺癌根治术后长期辅助雄激素剥夺治疗的终止：可行吗？
Jpn J Clin Oncol. 2016 Dec;46(12):1143-1147. doi: 10.1093/jjco/hyw136. Epub 2016 Sep 12.
7
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.根治性前列腺切除术（GETUG-AFU 16）后 PSA 浓度升高时的挽救性放疗联合或不联合短期激素治疗：一项随机、多中心、开放性 3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):747-756. doi: 10.1016/S1470-2045(16)00111-X. Epub 2016 May 6.
8
Controversies in the treatment of prostate cancer with maximal androgen deprivation.去势抵抗性前列腺癌治疗中的争议
Surg Oncol Clin N Am. 1995 Apr;4(2):345-59.
9
Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.前列腺癌根治术后复发高危患者的辅助治疗。
Eur Urol. 1997;32 Suppl 3:65-9.
10
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.雄激素剥夺治疗的时机及其对前列腺癌根治术后生存的影响：一项匹配队列研究。
J Urol. 2008 May;179(5):1830-7; discussion 1837. doi: 10.1016/j.juro.2008.01.022. Epub 2008 Mar 18.

引用本文的文献

1
Prostate Cancer Survival by Risk and Other Prognostic Factors in Mallorca, Spain.西班牙马略卡岛的前列腺癌生存与风险和其他预后因素
Int J Environ Res Public Health. 2021 Oct 24;18(21):11156. doi: 10.3390/ijerph182111156.